scorecardresearch
Business Today
Subscribe
PMS Today US News India UPSTART Weather BT Shorts NRI Education Election
BT Golf BT Mindrush BT Best Banks
Clear all
Search

COMPANIES

No Data Found

NEWS

No Data Found
Sign in Subscribe
events
Special
  • BT tech today
  • BT 500 wealth creators summit
  • Economic Indicators
News
Cipla

Feedback

Cipla

 

More Stories on Cipla
Quality Large & Midcap Funds Offer Higher Safety With Decent Returns
9:14

Quality Large & Midcap Funds Offer Higher Safety With Decent Returns

Mar 19, 2025

In today's episode of Top Funds on Business Today TV, anchor Shailendra Bhatnagar discusses the performance and prospects of the DSP Equity Opportunities Fund. As Nifty continues to rally for the third consecutive day, with a steady rise of 0.28%, and Sensex also showing a positive trend, the episode dives into the details of this well-established fund. Launched in March 2000, the DSP Equity Opportunities Fund has delivered impressive returns since its inception, with a 17.6% CAGR since launch, and a 16% CAGR for the past 10 years. The episode explores the fund's top holdings, portfolio performance, and key stock picks including HDFC Bank, ICICI Bank, Kotak Bank, and Cipla, among others. With a strong AUM of ₹12,598 crores, the fund continues to be a popular choice for long-term investors. Watch this episode to understand more about the DSP Equity Opportunities Fund, its historical performance, and the market outlook. Disclaimer: The information provided in this video is for informational purposes only and should not be construed as financial advice or stock recommendations. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cipla has given a strong breakout above its falling trendline resistance, signaling a shift in momentum towards the bulls, said the analyst.

Stock market today: Nifty levels to watch; trading views on Kotak Mahindra Bank, Cipla & Vedanta

Mar 19, 2025

An analyst from Master Capital said that Prices of Vedanta have exhibited strong bullish momentum, confirming a breakout above its trendline resistance.

Zydus Life has breached the critical Rs 910 level, a zone that previously attracted significant buying interest and fueled the rally to its all-time high., said the analyst.

Stock market today: Nifty levels to watch; trading views on Dr Reddys Labs, Cipla & Zydus Life

Mar 17, 2025

An analyst from Axis Securities said that Dr Reddy's Labs has shown signs of weakness following the formation of a double top around the Rs 1,400 level.

Stock recommendations by analyst for March 3: 'Buy' Kfin Technologies, MOFSL; 'Sell' Cipla

Stock recommendations by analyst for March 3: 'Buy' Kfin Technologies, MOFSL; 'Sell' Cipla

Mar 03, 2025

For Monday, an analyst from a domestic brokerage assigned 'Buy/Sell' calls on Kfin Technologies, MOFSL and Cipla shares. Check details.

Reaching for the Counters

Pharma majors cash in on demand for OTC drugs to diversify their revenue streams

Feb 26, 2025

Despite health concerns, the increasing popularity of OTC drugs has led to pharma majors seizing the chance to diversify their revenue streams. The rising popularity of skincare and personal health has led to easy access of several dermatological products. From D2C brands to established players, pharma companies are looking to bite into the pie.

Shares of BBTC, Cantabil Retail, Firstsource Solutions, Kirloskar Oil, Manappuram Finance, Nirlon, Procter & Gamble Health, SJVN and others shall trade ex-dividend today

Stocks in news: M&M, NTPC Green, Tata Steel, Cipla, Religare, RVNL & Delta Corp

Feb 21, 2025

Stocks including Quality Power, M&M, NTPC Green, Tata Steel, Cipla, RVNL, Delta Corp, HG Infra and Berger Paints will be in the spotlight on Friday, February 21.

Varun Beverages, Grasim, Eicher Motors, Apollo Hospitals, Patanjali Foods, Crisil, Nykaa, Nalco, Escorts Kubota, Gillette, Neuland Labs, Signatureglobal, Bata and more will announce their Q3 results on Monday, February 10.

Stocks in news: LIC of India, Bharat Electronics, Vedanta, Glenmark Pharma, Cipla, FirstCry & NHPC

Feb 10, 2025

Stocks including LIC, Bharat Electronics, Vedanta, Glenmark Pharma, Cipla, FirstCry, NHPC, VA Tech Wabag and more will be in the spotlight on Monday, February 10.

The FM announced to fully exempt as many as 36 lifesaving drugs from the customs duty, while presenting the Union Budget 2025-26 earlier today.

Budget 2025: Pfizer, Novartis, AstraZeneca to benefit from BCD exemptions; pharma stocks mixed

Feb 01, 2025

Budget 2025: Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of the budget announcements.

Raghvendra Singh said Suzlon's stock has seen huge selling pressure.

Suzlon Energy, Dixon, Kaynes, Cipla & Sun Pharma: What Raghvendra Singh says on these 5 stocks ahead of Budget

Jan 29, 2025

"Ahead of the Union Budget 2025 presentation, there could be some volatility in the market. Post-Budget, there may be a relief rally towards 24,000 level. We can expect some good news for the water-based management and banking sectors," the market expert told Business Today.

Paytm had a possible exhaustion in its upward momentum after reaching its peak. It has breached its 20-day and 50-day SMA’s, said the analyst.

Tata Motors, Paytm, Cipla: How to trade these 3 buzzing stocks

Jan 09, 2025

An analyst from YES Securities said that Tata Motors has undergone a significant correction from its peak of Rs 1,179 over the past five months, reaching oversold territory.

Pharma Stocks Buzzing | Raghvendra Singh: Sun Pharma, Cipla, Dr. Reddy’s Leading The Charge
1:29

Pharma Stocks Buzzing | Raghvendra Singh: Sun Pharma, Cipla, Dr. Reddy’s Leading The Charge

Nov 29, 2024

On Friday, November 29th, the pharmaceutical sector showed strong performance with Sun Pharma closing up by 3% and Cipla rising nearly 3%. The Nifty Pharma Index also climbed 2.35%, reflecting optimism in the sector. Market Expert Raghvendra Singh shared his insights on the outlook and strategy for pharma stocks. He emphasized that with the robust breakout in stocks like Cipla, Sun Pharma, and Dr. Reddy's, participation in the sector is crucial. He highlighted the impressive rollovers of 90%-95% in the pharma sector during the last month, suggesting a solid foundation for the next leg of the rally. Singh also pointed out that along with pharma, metals and PSU banks are expected to lead the markets higher, driving momentum for Nifty and Bank Nifty. Pharma stocks like Sun Pharma, Aurobindo Pharma, and Dr. Reddy's are positioned for significant upside, making them attractive for investors as the rally gains strength.

Load More

HOT STOCKS

  • NSE
  • BSE
Most active stocks that’s creating maximum buzz in the share market

TOP VIDEOS

Advertisement